Editas Medicine(EDIT.US)

Last Updated 19:00:00 ET
longbridge loading

CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?

nasdaq·
US
CRSP
-0.86%
US
EDIT
+2.46%
US
BBH
-0.17%
nasdaq·
US
CRSP
-0.86%
US
EDIT
+2.46%
US
BBH
-0.17%

Top Biotech Gainers: QTTB Has A Good Hair Day, GH Wins ACS Recommendation, Ebola Lifts SNGX, NNVX

rttnews·
US
QTTB
-0.47%
US
EDIT
+2.46%
US
LNAI
-3.60%
rttnews·
US
QTTB
-0.47%
US
EDIT
+2.46%
US
LNAI
-3.60%

Editas Medicine Announces Proposed Public Offering | EDIT Stock News

StockTitan·
US
EDIT
+2.46%
US
LABU
+2.37%
US
BIB
+0.46%
StockTitan·
US
EDIT
+2.46%
US
LABU
+2.37%
US
BIB
+0.46%

Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering | EDIT Stock News

StockTitan·
US
EDIT
+2.46%
US
IBB
+0.10%
US
BBH
-0.17%
StockTitan·
US
EDIT
+2.46%
US
IBB
+0.10%
US
BBH
-0.17%
© 2026 Longbridge｜Disclaimer